Financial Performance - In Q1 2023, the total revenue reached CNY 95,539,491.61, representing a year-on-year increase of 76.57%[5] - The net profit attributable to shareholders was CNY 30,081,694.57, up 76.85% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 26,468,101.27, showing a significant increase of 190.81% year-on-year[5] - Basic earnings per share were CNY 0.4406, reflecting a growth of 77.02%[6] - The total revenue for Q1 2023 was CNY 95,539,491.61, representing a 76.6% increase compared to CNY 54,107,297.63 in Q1 2022[19] - The net profit for Q1 2023 was CNY 30,081,694.57, which is a 76.9% increase from CNY 17,009,682.26 in Q1 2022[20] - The basic earnings per share for Q1 2023 was CNY 0.4406, compared to CNY 0.2489 in Q1 2022, reflecting a 77.0% increase[21] Expenses and Costs - Research and development expenses totaled CNY 15,218,176.47, which accounted for 15.93% of total revenue, a decrease of 13.30 percentage points[6] - The total operating costs for Q1 2023 were CNY 71,236,099.36, up from CNY 48,757,775.32 in Q1 2022, indicating a 46.0% increase[19] - The cash paid for purchasing goods and services in Q1 2023 was CNY 33,875,389.57, compared to CNY 16,103,900.51 in Q1 2022, which is a 109.0% increase[22] - The cash paid to employees in Q1 2023 was CNY 49,138,726.29, an increase from CNY 39,188,076.44 in Q1 2022, representing a 25.4% rise[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,721,089,251.57, an increase of 2.19% from the end of the previous year[6] - Total assets as of March 31, 2023, amounted to CNY 1,721,089,251.57, an increase from CNY 1,684,216,383.26 at the end of 2022[15] - Cash and cash equivalents decreased slightly to CNY 1,241,734,956.78 from CNY 1,248,127,080.91[15] - Accounts receivable decreased to CNY 20,378,378.62 from CNY 21,109,272.25, indicating a reduction of approximately 3.46%[15] - Inventory increased to CNY 38,582,312.84 from CNY 34,835,234.85, reflecting an increase of about 10.00%[15] - Total current liabilities rose to CNY 140,512,900.29 from CNY 129,243,639.61, representing an increase of approximately 8.83%[16] - Non-current assets totaled CNY 402,254,702.91, up from CNY 365,006,831.25, marking an increase of about 10.19%[16] - The total liabilities as of Q1 2023 were CNY 167,225,222.37, compared to CNY 155,669,156.83 in the previous year, showing a 7.4% increase[17] - The total equity attributable to shareholders as of Q1 2023 was CNY 1,553,864,029.20, up from CNY 1,528,547,226.43 in Q1 2022, indicating a 1.7% increase[17] - The deferred income tax liabilities decreased to CNY 532,680.04 from CNY 550,724.95, reflecting a 3.3% decrease[17] Cash Flow - Cash flow from operating activities was CNY 11,154,972.16, with no applicable year-on-year comparison[5] - The net cash flow from operating activities for Q1 2023 was $11,154,972.16, a significant improvement compared to a negative cash flow of $4,026,720.88 in Q1 2022, representing a turnaround of over 375%[23] - The total cash outflow from financing activities was $5,159,439.43, compared to $676,260.23 in Q1 2022, indicating an increase of over 663%[23] - The company reported a total cash outflow from operating activities of $113,087,236.15, which is an increase of approximately 34% compared to $84,452,766.78 in Q1 2022[23] - The cash flow from investment activities included cash received from the recovery of investments amounting to $655,000,000.00, down from $1,131,700,000.00 in the previous year, a decrease of about 42%[23] - The company paid $18,593,403.16 for the acquisition of fixed assets and intangible assets, which is an increase from $10,782,947.36 in Q1 2022, reflecting a growth of approximately 72%[23] Shareholder Information - The company has a total of 5,080 common shareholders as of the report date[12] - The top shareholder, Wang Zhiyu, holds 39.29% of the shares, totaling 26,961,547 shares[12] Strategic Developments - The company has not disclosed any significant new strategies or product developments in this report[14]

证券代码：688580 证券简称：伟思医疗 公告编号：2023-019 南京伟思医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 10 日(星期三)下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 28 日(星期五)至 05 月 09 日(星期二)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@vishee.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 南京伟思医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布《2022 年年度报告》和《2023 年第一季度报告》，为便于广大投资者更 全面深入地了解公司 2022 年度、2023 年第一 ...

VISHEE 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 3 月） 证券代码：688580 证券简称：伟思医疗 | --- | --- | |----------------------|------------------------------------------------------------------------| | | | | 活动时间： | | | 2022/03/01 | 10:00-11:00 | | 2022/03/03 | 10:00-12:00 | | 2022/03/04 | 14:00-15:00 | | 2022/03/15 | 10:00-12:00 | | 2022/03/28 | 10:00-11:00 | | 2022/03/30 | 14:00-15:00 | | 活动地点： | | | 南京市雨花台区宁双路 | 19 号 9 栋公司会议室 | | 参加单位名称： | | | | 方正证券、清水源、国寿安保基金、天虫资本、拓璞基金、泰达宏利、上 | | | 海涌津投资、中信建投、财通基金、兴业基金、新华基金、璞远资产、兴业资 | | | ...

VISHEE #恩 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 4 月） 证券代码：688580 证券简称：伟思医疗 活动时间： 2022/04/27 20:00-21:00 2022/04/28 10:00-11:00 2022/04/29 09:00-10:00 2022/04/29 10:00-11:00 2022/04/29 13:00-14:00 2022/04/29 14:00-15:00 2022/04/29 15:00-16:00 活动地点： 南京市雨花台区宁双路 19 号 9 栋公司会议室 参加单位名称： 长青基业、陕西海拓、钧荷资产、中信建投、苏豪投资、铭丰资本、国寿 安保基金、万方、上汽投资、璞远资产、中国人保资产、深圳瑞福资产、西藏 源乘投资、朴易投资、中欧基金、上海易正朗投资、凯石基金、HBM PARTNERS HONGKONG、宝盈基金、玖鹏资产、华泰证券、国泰君安、进化论资产、同泰基 金、东方医药、上银基金、上海顶天投资、域秀资产、中车资本、Yunqi Path、 瀚伦投资、深圳清水源投资、固禾资产、臻宜投资、朴易资产、中信保诚、湘 楚资产、博裕资本、泰信 ...

VISHEE #思 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 6 月） 证券代码：688580 证券简称：伟思医疗 | --- | --- | |----------------|------------------------------------------------------------------------| | | | | 活动时间: | | | 2022/6/8 | 11:00-12:00、13:00-14:00 | | 2022/6/15 | 15:00-16:00 | | 2022/6/16 | 15:00-16:00 | | 2022/6/17 | 15:30-16:30 | | 2022/6/20 | 14:00-15:00 | | 2022/6/21 | 15:30-16:30 | | 2022/6/22 | 09:30-10:30、13:00-16:00 | | 2022/6/24 | 10:00-11:00 | | 2022/6/27 | 10:30-11:30、13:30-14:30、16:00-17:00 | | 2022/6/28 | 10:0 ...

VISHEE #思 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 5 月） 证券代码：688580 证券简称：伟思医疗 | --- | |--------------------------------------------------------------------------| | | | 活动时间及地点： | | 2022/5/5 9:00-12:00、13:00-15:00 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/6 14:00-15:00 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/11 13:00-14:00 | | 上证路演中心网络互动（2021 年度暨 2022 年第一季度业绩说明会） | | 2022/5/11 15:30-16:30 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/18 15:00-16:00 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/19 15:00-16:00 | | 南京市雨花台区宁双路 19 号 ...

2022 年第三季度报告 证券代码：688580 证券简称：伟思医疗 南京伟思医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度(%) | 年初至报告期末 | 年初至报告期末比上年 同期增减变动幅度(%) | | --- | --- | --- | --- | --- | | 营业收入 | 82,454,129.32 | -26.30 | 216,579,425.15 | -28.60 | | 归属于上市 公司股东的 净利润 | 23,9 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company's operating revenue for the first half of 2022 was CNY 134.13 million, a decrease of 29.94% compared to the same period last year[19]. - Net profit attributable to shareholders for the same period was CNY 38.26 million, down 44.70% year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 27.04 million, a decline of 53.09% compared to the previous year[19]. - Basic earnings per share decreased to CNY 0.5601, down 44.67% from CNY 1.0122 in the same period last year[20]. - The company achieved total operating revenue of 134.13 million yuan, a year-on-year decrease of 29.94%[92]. - The company reported a total revenue of 10,427.81 million RMB for the first half of 2022, an increase from 8,367.70 million RMB in the same period last year[65]. - The company reported a net profit margin of 12% for the first half of 2022, an increase from 10% in the same period last year[120]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 500,000 users by June 30, 2022[1]. - User data showed a growth of 25% in active users, reaching 5 million by the end of June 2022[117]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - Market expansion plans include entering two new international markets by Q4 2022, which are projected to add 300 million in annual revenue[120]. Product Development and Innovation - New product development includes the launch of a rehabilitation robot, which is projected to contribute RMB 30 million in revenue by the end of 2022[1]. - The introduction of new products such as MyOnyx and MyoTrac series, which are marketed as biofeedback devices, is expected to enhance the company's market position[11]. - The company has launched multiple rehabilitation robot products, including X-walk100, X-walk200/300, and X-locom100, with X-walk400 in the registration phase and X-locom200/300 preparing for market entry[27]. - The company has developed a compact high-pressure medical power supply for magnetic stimulation products, achieving continuous output requirements of 100Hz pulse frequency and 6Tesla magnetic field strength[49]. - The company has completed the development of a prototype for a magnetic stimulation system aimed at depression, with ongoing work on automatic detection algorithms and clinical validation[60]. Research and Development - The company has invested RMB 5 million in R&D for new technologies in rehabilitation medical devices[1]. - Research and development expenses accounted for 24.43% of operating revenue, an increase of 9.74 percentage points year-on-year[20]. - The total R&D investment amounted to ¥32,762,412.42, an increase of 16.51% compared to the previous year, with the proportion of R&D investment to operating income rising to 24.43%, up by 9.74 percentage points[58]. - The R&D personnel count increased to 172, representing 27.09% of the total workforce, compared to 151 and 26.92% in the previous year[69]. Strategic Initiatives - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product offerings and increase market penetration[1]. - The company is actively pursuing international patent applications under the Patent Cooperation Treaty (PCT) to protect its innovative technologies[11]. - The company aims to enhance its operational efficiency through potential mergers and acquisitions in the healthcare technology space[10]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 250 million allocated for potential deals in 2022[120]. Financial Guidance and Future Outlook - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% compared to the first half[1]. - Future outlook includes a strategic emphasis on developing new technologies to address cognitive function disorders and neonatal brain injuries[11]. - The financial guidance for the upcoming quarters indicates a projected revenue growth of approximately 15% year-over-year, driven by new product launches and market expansion efforts[12]. - The company provided guidance for the second half of 2022, expecting revenue to reach between 1.5 billion and 1.7 billion, which would represent a growth of 20% to 30% compared to the same period last year[120]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company is closely monitoring industry policies and macroeconomic conditions to mitigate potential risks[90][91]. Compliance and Governance - The company has ensured compliance with all commitments made during the reporting period, with no noted failures to fulfill these commitments[115]. - The company commits to strictly adhere to the "Stabilization Plan for Stock Prices" as per relevant regulations, ensuring all obligations are fulfilled[149]. - The company guarantees that all information submitted to the China Securities Regulatory Commission and the Shanghai Stock Exchange is accurate and complete, taking legal responsibility for any misrepresentation[180].

Financial Performance - The company achieved total operating revenue of CNY 430.04 million in 2021, representing a year-on-year growth of 13.66%[27]. - Net profit attributable to shareholders reached CNY 177.81 million, an increase of 23.77% compared to the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 150.14 million, reflecting a growth of 16.98% year-on-year[27]. - The company's total assets at the end of 2021 amounted to CNY 1,638.74 million, a 6.38% increase from the previous year[25]. - The net assets attributable to shareholders were CNY 1,533.06 million, up by 9.04% compared to the end of 2020[25]. - Basic earnings per share for 2021 were CNY 2.6016, a 5.72% increase from CNY 2.4608 in 2020[26]. - The financial performance for the last fiscal year showed a revenue increase of 20%, reaching approximately $50 million[16]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[153]. - The company reported a gross margin of 45%, an improvement from 42% in the previous year, indicating better cost management[153]. Research and Development - The company is investing in R&D for innovative technologies, including transcranial magnetic stimulation (TMS) and muscle electrical stimulation devices, to enhance treatment efficacy[15]. - Research and development expenses accounted for 14.77% of operating revenue, an increase of 5.71 percentage points from the previous year[26]. - The company achieved a total R&D investment of ¥63,519,526.79 in 2021, representing an 85.26% increase compared to ¥34,287,376.78 in the previous year[73]. - R&D expenses surged by 85.26% to 63,519,526.79 RMB year-over-year[119]. - The company has filed over 40 invention patents related to rehabilitation technology, showcasing its commitment to innovation and development in the field[67]. - The company has developed advanced magnetic stimulation technology, achieving continuous output requirements of 100Hz pulse frequency and 6Tesla magnetic field strength[66]. - The company is actively researching functional electrical stimulation and intelligent stimulation technologies to expand its rehabilitation offerings[68]. - The company has completed several major research projects, including the development of a stroke assessment system and training software, which have been successfully accepted[72]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 15% year-over-year, driven by new product launches and market expansion strategies[16]. - Market expansion efforts are underway, targeting both domestic and international markets, with a focus on increasing distribution channels[14]. - The company plans to pursue strategic acquisitions to enhance its product portfolio and market presence in the rehabilitation sector[16]. - The company aims to expand its market reach to secondary hospitals, community hospitals, and home rehabilitation services, reflecting a strategic shift in service delivery[131]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential mergers and acquisitions[153]. - The company plans to enter two new international markets by Q2 2024, aiming for a 5% contribution to overall revenue[154]. Product Development and Innovation - The company focuses on rehabilitation medical devices, including electrophysiological and magnetic stimulation devices, as well as rehabilitation robots[14]. - New product lines, such as the MyOnyx and MyoTrac series, are expected to contribute significantly to revenue growth in the upcoming fiscal year[15]. - The company launched new rehabilitation robot products, including X-walk100 and X-walk200/300, which were certified and went on sale by the end of the year[36]. - The company is expanding its product line to include picosecond lasers, radiofrequency, and shaping magnets, positioning itself as a key player in the domestic medical beauty energy source market[135]. - The company is preparing to launch three models of the X-locom series rehabilitation robots, aimed at patients with movement disorders and elderly individuals[135]. Corporate Governance - The company held a total of 8 supervisory board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[141]. - Independent directors actively participated in board meetings and provided insights on corporate governance and operational matters[141]. - The company has not faced any penalties from securities regulatory agencies in the past three years[166]. - The company plans to continue its focus on corporate governance and compliance with regulatory standards[145]. - The company has established a compensation and assessment committee to oversee the remuneration of directors and senior management[163]. Cash Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 13.01 per 10 shares, totaling approximately RMB 88.91 million, representing a cash dividend payout ratio of 50% for the year 2021[6]. - The cash dividend distribution plan has been approved by the board and will be submitted for shareholder approval[184]. - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profits to be distributed as cash dividends annually, provided there are no major investment plans[182]. - The company confirmed that the dividend distribution plan complies with its articles of association and shareholder resolutions[185]. Operational Efficiency - The company aims to improve operational efficiency by implementing advanced manufacturing technologies and optimizing supply chain management[16]. - The company employs a "sales-driven procurement" model, aligning production with sales forecasts and inventory levels to optimize supply chain efficiency[49]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the end of 2022[153]. - The company achieved a 40% increase in operational efficiency through the integration of facial recognition technology in its products[82]. Market Trends and Industry Insights - The demand for rehabilitation medical devices is expected to continue growing due to factors such as an aging population and rising chronic disease prevalence, alongside the implementation of the two-child policy[55]. - The magnetic stimulation device market in China is still in its early stages, having begun to scale around 2016, with applications primarily in mental and neurological rehabilitation[56]. - The overall rehabilitation medical industry is expected to grow due to increasing national income and heightened awareness of healthcare among residents[65]. - The market for magnetic stimulation rehabilitation medical devices in China is projected to grow at a compound annual growth rate (CAGR) of 52.0%, reaching 1.78 billion CNY by 2023[129]. - The rehabilitation robot market in China is expected to grow at a CAGR of 57.5%, reaching 2.04 billion CNY by 2023, indicating significant growth potential[130].

Financial Performance - The total revenue for Q1 2022 was CNY 54,107,297.63, representing a year-on-year decrease of 32.53%[5] - The net profit attributable to shareholders was CNY 17,009,682.26, down 45.62% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 9,101,425.65, a decline of 64.88% year-on-year[5] - Basic earnings per share were CNY 0.2489, down 45.62% year-on-year[6] - Total operating revenue for Q1 2022 was ¥54,107,297.63, a decrease of 32.5% compared to ¥80,199,797.02 in Q1 2021[20] - Net profit for Q1 2022 was ¥17,009,682.26, a decline of 45.0% from ¥31,143,408.53 in Q1 2021[21] - Basic earnings per share for Q1 2022 were ¥0.2489, compared to ¥0.4577 in Q1 2021, reflecting a decrease of 45.6%[22] Cash Flow - The cash flow from operating activities was negative at CNY -4,026,720.88, reflecting a decrease of 165.22%[6] - Cash inflow from operating activities in Q1 2022 was ¥80,426,045.90, down 10.6% from ¥89,860,727.29 in Q1 2021[23] - The net cash flow from operating activities was -$4,026,720.88, a decrease compared to $6,173,884.92 in the previous year[24] - Total cash outflow from operating activities was $84,452,766.78, slightly higher than $83,686,842.37 in the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,633,238,657.53, a slight decrease of 0.34% from the end of the previous year[6] - As of March 31, 2022, the total current assets amounted to ¥1,420,724,782.34, a slight decrease from ¥1,434,334,932.56 at the end of 2021, reflecting a change of approximately -0.95%[16] - The total liabilities as of Q1 2022 were ¥81,056,182.35, down 23.4% from ¥105,679,873.40 in Q1 2021[20] - Current liabilities increased, with accounts payable rising to ¥9,547,293.70 from ¥9,279,529.62, an increase of approximately 2.9%[17] Research and Development - Research and development expenses totaled CNY 15,816,919.49, which is 29.23% of total revenue, an increase of 16.39 percentage points[6] - Research and development expenses for Q1 2022 were ¥12,926,343.65, an increase of 25.5% from ¥10,297,726.89 in Q1 2021[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,761[13] - The largest shareholder, Wang Zhiyu, holds 39.45% of the shares, totaling 26,961,547 shares[13] Other Information - The company implemented a restricted stock incentive plan, resulting in a post-tax share-based payment expense of CNY 3,954,600[7] - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[15] - There are no significant changes in the shareholder structure or any new mergers and acquisitions reported during the quarter[15] - The company did not report any new product launches or significant market expansions during this quarter[24] - The company is not applying the new accounting standards for the current year[25]